secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapsoVision, Inc (CV)
CIK:        0001378325
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001378325-25-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CapsoVision Q3 revenue $3.5M (+19% YoY); FDA submission for pancreatic cancer capsule
--------------------------------------------------------------------------------

- Revenue $3.5M (+19% YoY); new accounts up 31%; CapsoCam Plus used by 151k patients.
- Gross profit $1.9M (+16%); gross margin 54% vs 56% in Q3 2024.
- Operating expenses $9.9M (+$2.5M) driven by Canon CMOS development and public company costs.
- Cash $17.8M; July 2025 IPO net proceeds $23.4M.
- Submitted FDA Breakthrough Device Designation for early-stage pancreatic cancer detection; David Garcia appointed SVP Finance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1378325/000137832525000039/0001378325-25-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1378325/000137832525000039/cv-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001378325-25-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer